retatrutide type 2 diabetes trial results 2024 π¨Breaking: Retatrutide's first Phase 3 T2D data just dropped. βΈ A1C: β2.0% at 40 weeks βΈ Weight: β36.6 lbs (β16.8%) at 12 mg βΈ No weight loss plateau β curve still descending Advancements in Clinical Research and
Description
This update follows more than 8,500 reports of gastrointestinal disorders associated with semaglutide medications, with 33 cases specifically mentioning ileus, including two deaths
No h justificativa para no ter ao menos a sibutramina, de baixo custo, no SUS. +Leia Tambm: Como melhorar o acesso ao tratamento da obesidade no pas
No dose adjustment needed
A substudy of the main study, presented here, enrolled participants who qualified for the main study and also had MASLD with a liver fat content of 10% or greater identified by MRIPDFF
